CONSTELLATION PHARMACEUTICALS
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
CONSTELLATION PHARMACEUTICALS
Industry:
Biotechnology Genetics Medical Pharmaceutical
Founded:
2008-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.constellationpharma.com
Total Employee:
101+
Status:
Closed
Contact:
6177140555
Email Addresses:
[email protected]
Total Funding:
496.2 M USD
Technology used in webpage:
SPF Apple Mobile Web Clips Icon Mobile Non Scaleable Content Euro Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS COVID-19
Similar Organizations
Actinium Pharmaceuticals
Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops precise medicines for human disease.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - Constellation Pharmaceuticals
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Constellation Pharmaceuticals
The Column Group
The Column Group investment in Post-IPO Equity - Constellation Pharmaceuticals
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Constellation Pharmaceuticals
Deerfield
Deerfield investment in Series F - Constellation Pharmaceuticals
Hillhouse Capital Group
Hillhouse Capital Group investment in Series F - Constellation Pharmaceuticals
NS Investment
NS Investment investment in Series F - Constellation Pharmaceuticals
The Column Group
The Column Group investment in Series F - Constellation Pharmaceuticals
SR One
SR One investment in Series F - Constellation Pharmaceuticals
Venrock
Venrock investment in Series F - Constellation Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2020-06-08 | Constellation Pharmaceuticals Announces Appointment of Dr. Jeffrey Humphrey as Chief Medical Officer |
Official Site Inspections
http://www.constellationpharma.com
- Host name: 104.18.28.230
- IP address: 104.18.28.230
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Constellation Pharmaceuticals"
Constellation Pharmaceuticals - Crunchbase Company Profile
Contact Email [email protected] Phone Number 6177140555 Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel …See details»
Constellation Pharmaceuticals, Inc. - Drug pipelines, Patents, …
Www.constellationpharma.com. Public Company | Subsidiary Company | 2008 | Massachusetts, United States | 100-250 | NASDAQ: CNST | www.constellationpharma.com. Last update 01 …See details»
Constellation Pharmaceuticals Inc - Company Profile - GlobalData
Constellation Pharmaceuticals Inc (Constellation), a subsidiary of MorphoSys US Inc, is a clinical biopharmaceutical company that focuses on the development of novel therapeutics for the …See details»
Constellation Pharmaceuticals - PitchBook
Constellation Pharmaceuticals General Information Description. Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel …See details»
Constellation Pharmaceuticals, Inc. - AnnualReports.com
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical …See details»
Constellation Pharmaceuticals Inc - Company Profile and News
Company profile page for Constellation Pharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»
MorphoSys to Acquire Constellation Pharmaceuticals
Jun 2, 2021 Strengthens Cutting-Edge Research and Technology Organization. ... Investor Relations and Communications Constellation Pharmaceuticals +1 617-844-6859 …See details»
MorphoSys AG to Acquire Constellation Pharmaceuticals and …
Jun 2, 2021 MorphoSys also announced that it has entered into a long-term strategic funding partnership with Royalty Pharma plc (NASDAQ: RPRX) ("Royalty Pharma") (together with the …See details»
Constellation Pharmaceuticals - VentureRadar
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small-molecule therapies based on its pioneering... ... Find out more ...See details»
Constellation Pharmaceuticals - Craft
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel drugs that address serious unmet medical needs in patients with cancers …See details»
Working at Constellation Pharmaceuticals - Zippia
Mar 14, 2024 www.constellationpharma.com. Organization Type. Public. CEO. Jigar Raythatha. Social Media. Constellation Pharmaceuticals is the first biopharmaceutical company dedicated …See details»
Constellation Pharmaceuticals - Golden
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using epigenetics for the development of therapeutics for the selective targeting and modulating of gene …See details»
Constellation Pharmaceuticals Appoints Mark A. Goldsmith, M
Aug 13, 2009 “With its world-class founders, organization and investors, Constellation is emerging as the leading drug discovery player and corporate partner in the exciting field of …See details»
Constellation Pharmaceuticals Announces Fourth-Quarter and Full …
Feb 24, 2021 Contacts Kia Khaleghpour, Ph.D. Vice President, Investor Relations and Communications Constellation Pharmaceuticals +1 617-844-6859 …See details»
Constellation Pharmaceuticals Closes $22 Million in Series B Funding
Jun 2, 2010 Constellation Pharmaceuticals Closes $22 Million in Series B Funding -Proceeds to Broaden Leading Epigenetics Product Engine and Advance Pipeline towards the Clinic- …See details»
Constellation Pharmaceuticals Announces First-Quarter 2021
May 10, 2021 General and administrative (G&A) expenses grew 59.8% year over year to $9.4 million in the first quarter of 2021, primarily due to building out the organization of the company.See details»
Constellation Pharmaceuticals CEO and Key Executive Team
Constellation Pharmaceuticals's Chief Business Officer is Barbara Krebs-Pohl. See the full leadership team at Craft.See details»
Constellation Pharmaceuticals Announces Second-Quarter 2020 …
Aug 5, 2020 * Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20 * Constellation plans to explore …See details»
MorphoSys to Acquire Constellation Pharmaceuticals
Jun 2, 2021 - Strengthens Cutting-Edge Research and Development Organization. ... [email protected]. Royalty Pharma Contacts Investor Contact +1 …See details»
Constellation Pharmaceuticals Provides an Update from the
Jun 11, 2021 Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with...See details»